Welcome to our dedicated page for COLLEGIUM PHARMACEUTICAL SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
Collegium Pharmaceutical completed its acquisition of AZSTARYS, a CNS stimulant for ADHD, for approximately $650 million in cash, funded with about $350 million of existing cash and a $300 million delayed draw term loan. The deal also includes up to $135 million in milestone payments. Collegium raised its 2026 guidance, now expecting total product revenues, net of $865 to $895 million and adjusted EBITDA of $475 to $500 million, including expected AZSTARYS net revenue of $60 to $70 million for the remainder of 2026 and annual run rate synergies expected to exceed $50 million within twelve months. AZSTARYS generated more than 760,000 prescriptions in 2025 and is supported by six Orange Book-listed patents, most expiring in December 2037. The company also adopted a 2026 Inducement Plan covering up to 325,000 shares for new hires and announced upcoming departures of its Chief Commercial Officer and Chief Medical Officer, both treated as terminations without cause with transition periods.
Invesco Ltd. reports beneficial ownership of 1,591,909 shares of Collegium Pharmaceutical Inc. common stock, representing 5.0% of the class. The filing states Invesco Ltd. has sole voting power for 1,490,397 shares and sole dispositive power for 1,591,909 shares.
Collegium Pharmaceutical reported significantly stronger quarterly results. For the three months ended March 31, 2026, product revenues, net were $193.5 million, up from $177.8 million a year earlier, driven by growth across Belbuca, Xtampza ER, Jornay PM and Symproic. Net income rose to $14.5 million from $2.4 million, with diluted earnings per share increasing to $0.40 from $0.07.
Cash, cash equivalents and restricted cash totaled $289.6 million, while total debt, including term notes and convertible senior notes, remained substantial. Collegium also signed an agreement to acquire AZSTARYS® for $650 million in cash plus up to $135 million in milestones, aiming to further expand its neuropsychiatry portfolio following the Ironshore acquisition and Jornay PM integration.
Collegium Pharmaceutical reported strong first quarter 2026 results and reiterated its full-year outlook. Product revenues, net were $193.5 million, up 9% year-over-year, driven by ADHD drug JORNAY PM net revenue of $38.9 million, up 36%, and pain portfolio revenue of $154.6 million, up 4%.
GAAP net income rose to $14.5 million, while non-GAAP adjusted net income reached $69.2 million and adjusted EBITDA was $103.9 million, both up 9% year-over-year. The company ended the quarter with $421.8 million in cash, cash equivalents and marketable securities and generated $57.1 million in operating cash flow.
Collegium reaffirmed 2026 guidance for product revenues, net of $805–$825 million, JORNAY PM revenue of $190–$200 million, and adjusted EBITDA of $455–$475 million, excluding the planned acquisition of ADHD medicine AZSTARYS. The AZSTARYS deal totals $650 million in cash plus up to $135 million in milestones and is expected to be immediately accretive to adjusted EBITDA after an anticipated close in the second quarter of 2026.
Collegium Pharmaceutical is asking shareholders to elect eight directors, approve executive pay on an advisory basis, and ratify Deloitte & Touche as auditor at its fully virtual 2026 annual meeting. Shareholders of record on March 31, 2026, representing 32,406,969 shares, may vote online, by phone, mail or during the webcast.
The proxy highlights record 2025 product revenue of $780.6 million, up 23.6%, driven by Jornay PM net revenue of $148.9 million with 48% year-over-year growth and a pain portfolio generating $631.7 million, up 6%. Operating cash flow reached $329.3 million, year-end cash and marketable securities were $386.7 million, and the company closed a $980 million syndicated credit facility while repaying about $581 million of prior term debt.
Collegium returned $25 million to shareholders via repurchases, reports strong governance with seven of eight independent directors, and emphasizes ESG initiatives, employee development, and culture. The compensation program is positioned as pay-for-performance, with a prior say-on-pay vote receiving approximately 91% support.
Collegium Pharmaceutical, Inc. announced changes to its board of directors. The board approved the nomination of Michael Donovan, 60, an audit Partner at Ernst & Young LLP since 2002, to stand for election at the 2026 Annual Meeting of Shareholders.
The company also disclosed that John Fallon, M.D., a director since 2016, will not stand for re-election and will retire from the board at the Annual Meeting. His decision is described as part of ongoing board refreshment and succession planning and not due to any disagreement with the company.
Collegium Pharmaceutical executive David Dieter reported a routine share disposition tied to tax withholding. On the vesting of restricted stock units, 8,840 shares of common stock were withheld by the company at $35.72 per share to cover applicable withholding taxes. After this non-market transaction, he directly holds 68,231 shares of Collegium Pharmaceutical common stock.
Collegium Pharmaceutical Inc amendment: The Vanguard Group reports 0 shares beneficially owned of Collegium common stock following an internal realignment. The filing states that certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538 (January 12, 1998).
The disclosure lists 0 shares and 0% voting and dispositive power in the issuer’s common stock and is signed by Vanguard’s Head of Global Fund Administration.